ADAGIO MEDICAL HOLDINGS INC

ADGMNASDAQ

🏆 #3691 by market capEarnings Aug 14US Equity

$0.72▼ $0.02 (−3.37%)

🌙 After hours$0.70▼ 2.93%Regular close · extended-hours price shown

1h—

24h▼ 3.4%

7d▼ 0.4%

14d▲ 48.8%

30d▲ 21.2%

1y▼ 44.7%

🏦Market Cap

$16M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $0.71 – $0.73
52-Week Range: $0.36 – $2.58
Volume: $2.44B
Avg Volume: $2.64B
Shares Outstanding: 22.2M
Next Earnings: Sep 9, 2026

Fundamentals Snapshot

Annual Revenue: $3M
Last Q Revenue: $726,977
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.39
Dividend Yield: —

Why Investors Own ADGM

✓High-growth profile — revenue up +11.2% YoY with expanding US Equity exposure.
✓Healthy economics — 72% gross margin and 29% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$3M▲ +7.6% YoY

Gross Margin (TTM)

71.8%▲ +4.2% YoY

Operating Income (TTM)

$970,103▲ +7.6% YoY

Free Cash Flow (TTM)

$866,586▲ +7.6% YoY

About ADAGIO MEDICAL HOLDINGS INC

Adagio Medical Holdings, Inc. is an innovative biotechnology firm dedicated to revolutionizing the treatment of cardiac arrhythmias through advanced medical technologies. Utilizing its proprietary platform, the company is spearheading the development of targeted ablation techniques that address significant unmet needs in the electrophysiology sector. Supported by a robust product pipeline and a seasoned leadership team, Adagio represents an attractive investment opportunity for institutional investors seeking growth in the healthcare space while contributing to improved outcomes in cardiac patient care.

🦦